美国食品药品监督管理局（FDA）已为施贵宝（Bristol-Myers Squibb）的一项申请设定了目标审评日期——2026年8月17日。与此同时，FDA还授予了该疗法突破性疗法认定以及优先审评资格。这一系列举措显著加速了该疗法的审评进程，体现了监管机构对其潜在临床价值的认可。
美国食品药品监督管理局（FDA）已为施贵宝（Bristol-Myers Squibb）的一项申请设定了目标审评日期——2026年8月17日。与此同时，FDA还授予了该疗法突破性疗法认定以及优先审评资格。这一系列举措显著加速了该疗法的审评进程，体现了监管机构对其潜在临床价值的认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.